Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8760770 | 1.00 | LTA4H (0.53) | LTA4HS1PR1S1PR3NPC1RAB9A | |
| SCHEMBL3954076 | 0.86 | LTA4H (0.67) | LTA4HS1PR1S1PR3SMN1; SMN2TAAR1 | |
| SCHEMBL2309395 | 0.86 | LTA4H (0.67) | LTA4HS1PR1S1PR3SMN1; SMN2TAAR1 | |
| SCHEMBL12886499 | 0.86 | SMN1; SMN2 (0.53) | LTA4HS1PR1S1PR3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL27450918 | 0.84 | LTA4H (0.65) | LTA4HS1PR1S1PR3TAAR1MEN1 | |
| Hydrochloric Acid SCHEMBL7363569 | 0.84 | LTA4H (0.65) | LTA4HS1PR1S1PR3TAAR1MEN1 | |
| Bromide SCHEMBL11428373 | 0.81 | TAAR1 (0.61) | LTA4HNPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL8761898 | 0.81 | MMP9 (0.57) | LTA4HMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8761863 | 0.81 | MMP9 (0.57) | LTA4HMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9116086 | 0.81 | LTA4H (0.45) | LTA4HSMN1; SMN2MEN1KMT2AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001022985-A9 | USE OF PENTAGASTRIN TO INHIBIT GASTRIC ACID SECRETION OR AS A DIURETIC | UNIV CALIFORNIA (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6384272-B2 | FORMATION OF AMMONIUM SALT OF (ALPHA-ASPARTYL)PHENYLALANINE BY AMIDATION OF ESTER OF (ALPHA-ASPARTYL)PHENYLALANINE, THEN (ALPHA-ASPARTYL)-BETA-CYCLOHEXYLALANINAMIDE IS OBTAINED BY CATALYTIC HYDROGENATION | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | AVENTIS PHARMA S.A. (FR) | 2001-10-25 | — | — | US | disclosed |
| WO-2001022985-A1 | USE OF PENTAGASTRIN TO INHIBIT GASTRIC ACID SECRETION OR AS A DIURETIC | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1013663-A1 | Synthesis and recovery of aspartame involving enzymatic deformylation step | Holland Sweetener Company V.O.F. (NL) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | ASNS, DNPEP, ANPEP | LTA4H 1778/4885S1PR1 3785/4885S1PR3 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.